Yongfang Jiang

139 Renmin Middle Road
Changsha, 410011, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 64 publications

VALID regimen of voriconazole optimizes therapeutic target attainment and minimizes adverse events in patients with liver dysfunction.

VALID regimen of voriconazole optimizes therapeutic target attainment and minimizes adverse events in patients with liver dysfunction.

Journal: Frontiers in pharmacology
Published: May 31, 2026

Clinical features of Q fever confirmed by plasma metagenomic next-generation sequencing.

Clinical features of Q fever confirmed by plasma metagenomic next-generation sequencing.

Journal: Frontiers in immunology
Published: April 04, 2026

Hepatocyte hnRNPK preserves mitochondrial integrity to restrain liver injury and fibrosis.

Hepatocyte hnRNPK preserves mitochondrial integrity to restrain liver injury and fibrosis.

Journal: Hepatology (Baltimore, Md.)
Published: March 30, 2026

Machine Learning Models Using Hospital Admission Characteristics Do Not Optimally Predict Nosocomial Infection Development in a Global Cirrhosis Cohort.

Machine Learning Models Using Hospital Admission Characteristics Do Not Optimally Predict Nosocomial Infection Development in a Global Cirrhosis Cohort.

Journal: The American journal of gastroenterology
Published: February 01, 2026

Chinese expert consensus on the combined use of antiviral drugs for influenza.

Chinese expert consensus on the combined use of antiviral drugs for influenza.

Journal: Bioscience trends
Published: October 29, 2025

Deciphering OCT4A-dose-dependent transcriptional profiles associated with tumorigenic potential in somatic cancer cells.

Deciphering OCT4A-dose-dependent transcriptional profiles associated with tumorigenic potential in somatic cancer cells.

Journal: SLAS technology
Published: September 17, 2025

Chinese expert consensus on the combined use of antiviral drugs for novel coronavirus infection.

Chinese expert consensus on the combined use of antiviral drugs for novel coronavirus infection.

Journal: Bioscience trends
Published: August 27, 2025

Machine learning model for HBsAg seroclearance after 48-week pegylated interferon therapy in inactive HBsAg carriers: a retrospective study.

Machine learning model for HBsAg seroclearance after 48-week pegylated interferon therapy in inactive HBsAg carriers: a retrospective study.

Journal: Virology journal
Published: August 03, 2025

Diagnostic delays in alcoholic cirrhosis: A cross-sectional study of contributing factors.

Diagnostic delays in alcoholic cirrhosis: A cross-sectional study of contributing factors.

Journal: World journal of gastroenterology
Published: June 16, 2025

Sofosbuvir/Velpatasvir/Voxilaprevir Versus Sofosbuvir/Velpatasvir Plus Ribavirin in Patients With Hepatitis C Virus Genotype 3b and Compensated Cirrhosis: A Multicentre Randomized Controlled Trial.

Sofosbuvir/Velpatasvir/Voxilaprevir Versus Sofosbuvir/Velpatasvir Plus Ribavirin in Patients With Hepatitis C Virus Genotype 3b and Compensated Cirrhosis: A Multicentre Randomized Controlled Trial.

Journal: Journal of medical virology
Published: May 25, 2025

Huangjia Ruangan granules with entecavir for fibrosis regression in Chroinc Hepatitis B: A multicenter, randomized, double-blind, phase II trial.

Huangjia Ruangan granules with entecavir for fibrosis regression in Chroinc Hepatitis B: A multicenter, randomized, double-blind, phase II trial.

Journal: Phytomedicine : international journal of phytotherapy and phytopharmacology
Published: May 04, 2025

Interim Analysis of 48-week Tenofovir Amibufenamide Treatment in Chronic Hepatitis B Patients with Normal Alanine Aminotransferase Levels: The PROMOTE Study.

Interim Analysis of 48-week Tenofovir Amibufenamide Treatment in Chronic Hepatitis B Patients with Normal Alanine Aminotransferase Levels: The PROMOTE Study.

Journal: Journal of clinical and translational hepatology
Published: April 15, 2025
Showing 1-12 of 64

Last Updated: 09/26/2026